Q5132 HCPCS Level II code: Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
CMS terminated Q5132: its last date of service was Dec 31, 2024. It stays here for looking up older claims; newer services need a current code.
Official description
Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
Short description: Inj, abrilada, 10 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q5132 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2024
- Terminated after
- Dec 31, 2024
Where Q5132 sits
- 1Q codesTemporary codes
- 2Terminated Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q5132 still valid?
No. CMS terminated Q5132; its last date of service was Dec 31, 2024. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q5132?
CMS lists Q5132’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q5132
All Q codesQ5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgQ5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mgQ5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mgQ5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgQ5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mgQ5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mgQ5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mgQ5134Injection, natalizumab-sztn (tyruko), biosimilar, 1 mgQ5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mgQ5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mgQ5137Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mgQ5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg